The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in Inflammatory Bowel Disease

Digestive and Liver Disease

Volumn 43, Issue 1, 2011, Pages 1-20

  Orlando, Ambrogio ^a   Armuzzi, Alessandro ^b   Papi, Claudio ^c   Annese, Vito ^d   Ardizzone, Sandro ^e   Biancone, Livia ^f   Bortoli, Aurora ^g   Castiglione, Fabiana ^h   D'Incà, Renata ⁱ   Gionchetti, Paolo ^j   Kohn, Anna ^k   Poggioli, Gilberto ^j   Rizzello, Fernando ⁱ   Vecchi, Maurizio ^l   Cottone, Mario ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c SAN FILIPPO NERI HOSPITAL   (Italy)

^d CAREGGI UNIVERSITY HOSPITAL   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f UNIVERSITY OF ROME TOR VERGATA   (Italy)

^g RHO HOSPITAL   (Italy)

^h UNIVERSITY OF NAPLES FEDERICO II   (Italy)

ⁱ UNIVERSITY OF PADOVA   (Italy)

^j UNIVERSITY OF BOLOGNA   (Italy)

^k SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^l IRCCS POLICLINICO SAN DONATO   (Italy)

more..

Author keywords

Biologics; Guidelines; Inflammatory Bowel Disease; Tumor necrosis factor alpha antagonist

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; INFLIXIMAB; MERCAPTOPURINE; METHYLPREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANUS FISTULA; ARTICLE; AUTOIMMUNITY; BACTERIAL INFECTION; BIOLOGICAL THERAPY; CANCER RISK; CONGESTIVE HEART FAILURE; CROHN DISEASE; CYTOMEGALOVIRUS INFECTION; DRUG SAFETY; ENTERITIS; EPSTEIN BARR VIRUS INFECTION; HEPATITIS B; HEPATITIS C; HERPES ZOSTER; HUMAN; ILEITIS; INFECTION RISK; INFLUENZA; INJECTION SITE REACTION; LIVER DISEASE; MAINTENANCE THERAPY; MYCOSIS; NEUROLOGIC DISEASE; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; RELAPSE; REMISSION; TUBERCULOSIS; ULCERATIVE COLITIS; VARICELLA ZOSTER VIRUS;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL FISTULA; ITALY; NEOPLASMS; OPPORTUNISTIC INFECTIONS; PREGNANCY; PREGNANCY COMPLICATIONS; REMISSION INDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78649912194     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2010.07.010     Document Type: Article

References (215)

1. Carter M.J., Lobo A.J., Travis S.P. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004, 53:V1-16. IBD Section, British Society of Gastroenterology.
2. Hoffmann J.C., Zeitz M., Bischoff S.C., et al. Diagnosis and therapy of ulcerative colitis: results of an evidence based consensus conference by the German Society of Digestive and Metabolic Diseases and the competence network on inflammatory bowel disease. Z Gastroenterol 2004, 42:979-983.
3. Clark M., Colombel J.F., Feagan B.C., et al. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology 2007, 133:312-339.
4. Sadowski D.C., Bernstein C.N., Bitton A., et al. Canadian Association of gastroenterology Clinical Practice Guidelines: the use of tumor necrosis factor-alpha antagonist therapy in Crohn's disease. Can J Gastroenterol 2009, 23:185-202.
5. Travis S.P.L., Stange E.F., Lémann M., et al. European evidence-based consensus on the diagnosis and management of ulcerative colitis: current management. J Crohn's Colitis 2008, 2:24-62.
6. Dignass A., Van Assche G., Lindsay J.O., et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohn's Colitis 2010, 4:28-62.
7. Bernstein C.N., Fried M., Krabshuis J.H., et al. World Gastroenterology Organization practice guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis 2010, 16:112-124.
8. Anonymous, Centre for Evidence Based Medicine, Oxford. Levels of evidence and grades of recommendation. http://www.cebm.net/levels_of_evidence.asp.
9. Best W.R., Becktel J.M., Singleton J.W., et al. Development of Crohn's disease activity index, National Cooperative Crohn's Disease Study. Gastroenterology 1976, 70:439-444.
10. Harvey R.F., Bradshaw J.M. A simple index of Crohn's disease activity. Lancet 1980, 8:514.
11. Sandborn W.J., Feagan B.G., Hanauer S.B., et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002, 122:512-530.
12. Rutgeerts P., D'Haens G., Targan S., et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999, 117:761-769.
13. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549.
14. Hanauer S.B., Sandborn W.J., Rutgeerts P., et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006, 130:323-333.
15. Vermeire S., Schreiber S., Sandborn W.J., et al. Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity. Clin Gastroenterol Hepatol 2010, 4:357-363.
16. Van Assche G., Dignass A., Panes J., et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohn's Colitis 2010, 4:7-27.
17. Caprilli R., Andreoli A., Capurso L., et al. Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Aliment Pharmacol Ther 1994, 8:35-43.
18. Rutgeerts P., Geboes K., Vantrappen G., et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990, 99:956-963.
19. Munkholm P., Langholz E., Davidsen M., et al. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994, 35:360-362.
20. Truelove S.C., Witts L.J. Cortisone in ulcerative colitis: final report on a therapeutic trial. Br Med J 1955, 2:1041-1048.
21. D'Haens G., Sandborn W.J., Feagan B.G., et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007, 132:763-786.
22. Stange E.F., Travis S.P.L., Vermeire S., et al. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohn's Colitis 2008, 2:1-23.
23. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462-2476.
24. Higgins P.D., Schwartz M., Mapili J., et al. Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut 2005, 54:782-788.
25. Rutgeerts P., Vermeire S., Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?. Gut 2007, 56:453-455.
26. Edwards F.C., Truelove S.C. The course and prognosis of ulcerative colitis. Gut 1963, 4:299-315.
27. Lichtiger S., Present D.H. Preliminary report: cyclosporin in treatment of severe active ulcerative colitis. Lancet 1990, 336:16-19.
28. Schroeder K.W., Tremaine W.J., Ilstrup D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987, 317:1625-1629.
29. Irvine E.J. Usual therapy improves perianal Crohn's disease as measured by a new disease activity index. McMaster IBD Study Group. J Clin Gastroenterol 1995, 20:27-32.
30. Irvine E.J., Feagan B., Rochon J., et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994, 106:287-296.
31. Mitchell A., Guyatt G., Singer J., et al. Quality of life in patients with inflammatory bowel disease. J Clin Gastroenterol 1988, 10:306-310.
32. Miller M.D., Ferris D.G. Measurement of subjective phenomena in primary care research: the Visual Analogue Scale. Fam Pract Res J 1993, 13:15-24.
33. Henriksen M., Jahnsen J., Lygren I., et al. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut 2008, 57:1518-1523.
34. Zilberman L., Maharshak N., Arbel Y., et al. Correlated expression of high-sensitivity C-reactive protein in relation to disease activity in inflammatory bowel disease: lack of differences between Crohn's disease and ulcerative colitis. Digestion 2006, 73:205-209.
35. Maharshak N., Arbel Y., Gal-Oz A., Rogowski O., et al. Comparative analysis of Bayer wide-range C-reactive protein (wr-CRP) and the Dade-Behring high sensitivity C-reactive protein (hs-CRP) in patients with inflammatory bowel disease. J Dig Dis 2008, 9:140-143.
36. D'Incà R., Dal Pont E., Di Leo V., et al. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis 2007, 22:429-437.
37. Tibble Ja, Sigthorsson G., Bridger S., et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000, 119:15-22.
38. Konikoff M.R., Denson L.A. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis 2006, 12:524-534.
39. Teahon K., Smethurst P., Levi A.J., et al. The effect of elemental diet on intestinal permeability and inflammation in Crohn's disease. Gastroenterology 1991, 101:84-89.
40. Wyatt J., Vogelsang H., Hubl W., et al. Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet 1993, 341:1437-1439.
41. Targan S.R., Hanauer S.B., van Deventer S.J., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997, 337:1029-1035.
42. Colombel J.F., Sandborn W.J., Rutgeerts P., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Gastroenterology 2007, 132:52-65.
43. Peyrin-Biroulet L., Deltenre P., de Suray N., et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008, 6:644-653.
44. Lémann M., Mary J.Y., Duclos B., et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 2006, 130:1054-1061.
45. Colombel J.F., Sandborn W.J., Reinisch W., et al. Infliximab, azathioprine or combination therapy for Crohn's disease. N Engl J Med 2010, 362:1383-1395.
46. Lofberg R., Louis E., Reinisch W., et al. Adalimumab effectiveness in TNF-antagonist-naïve patients and in infliximab nonresponders with Crohn's Disease: results from the Care Study. Am J Gastroenterol 2008, 103(Suppl 1):S418.
47. Sandborn W.J., Rutgeers P., Enns R., et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007, 146:829-838.
48. Sandborn W.J., Hanauer S.B., Rutgeerts P., et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007, 56:1232-1239.
49. Behm B.W., Bickston S.J. Tumor necrosis factor alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2008, 1:CD006893.
50. Mackey A.C., Green L., Liang L.C., et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007, 44:265-267.
51. Shale M., Kanfer E., Panaccione R., et al. Hepatosplenic T cell lymphoma in inflammatory bowel disease. Gut 2008, 57:1639-1641.
52. Ochenrider M.G., Patterson D.J., Aboulafia D.M. Hepatosplenic T-cell lymphoma in a young man with Crohn's disease: case report and literature review. Clin Lymphoma Myeloma Leuk 2010, 10:144-148.
53. Panaccione R., Colombel J.F., Sandborn W.J., et al. Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease. Aliment Pharmacol Ther 2010, [epub ahead of print].
54. Fidder H., Schnitzler F., Ferrante M., et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009, 58:501-508.
55. D'Haens G., Baert F., van Assche G., et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008, 371:660-667.
56. Schreiber S., Reinisch W., Colombel J.F. Early Crohn's disease shows high levels of remission to therapy with adalimumab: sub-analysis of CHARM. Gastroenterology 2007, 132:A985.
57. Beaugerie L., Seksik P., Nion-Larmurier I., et al. Predictors of Crohn's disease. Gastroenterology 2006, 130:650-656.
58. Rutgeerts P., Diamond R.H., Bala M., et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006, 63:433-442.
59. Schnitzler F., Fidder H., Ferrante M., et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009, 15:1295-1301.
60. Baert F., Moortgat L., van Assche G., et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010, 138:463-468.
61. Froslie K.F., Jahnsen J., Moum B.A., et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007, 133:412-422.
62. Rutgeerts P., D'Haens G.R., Van Assche G.A., et al. Adalimumab induces and maintains mucosal healing in patients with moderate to severe ileocolonic Crohn's disease-first results of the Extend trial. Gastroenterology 2009, 136. A-116.
63. Haggett P.J., Moore N.R., Shearman J.D., et al. Pelvic and perineal complications of Crohn's disease: assessment using magnetic resonance imaging. Gut 1995, 36:407-410.
64. Skalej M., Makowiec F., Weinlich M., et al. Magnetic resonance imaging in perianal Crohn's disease. Dtsch Med Wochenschr 1993, 118:1791-1796.
65. Koelbel G., Schmiedl U., Majer M.C., et al. Diagnosis of fistulae and sinus tracts in patients with Crohn disease: value of MR imaging. Am J Roentgenol 1989, 152:999-1003.
66. van Bodegraven A.A., Sloots C.E., Felt-Bersma R.J., et al. Endosonographic evidence of persistence of Crohn's disease-associated fistulas after infliximab treatment, irrespective of clinical response. Dis Colon Rectum 2002, 45:39-46.
67. Sloots C.E., Felt-Bersma R.J., Poen A.C., et al. Assessment and classification of fistula-in-ano in patients with Crohn's disease by hydrogen peroxide enhanced transanal ultrasound. Int J Colorectal Dis 2001, 16:292-297.
68. Orsoni P., Barthet M., Portier F., et al. Prospective comparison of endosonography, magnetic resonance imaging and surgical findings in anorectal fistula and abscess complicating Crohn's disease. Br J Surg 1999, 86:360-364.
69. Parks A.G., Gordon P.H., Hardcastle J. A classification of fistula-in-ano. Br J Surg 1976, 63:1-12.
70. Bell S.J., Williams A.B., Wiesel P., et al. The clinical course of fistulating Crohn's disease. Aliment Pharmacol Ther 2003, 17:1145-1151.
71. Bernstein L.H., Frank M.S., Brandt L.J., et al. Healing of perineal Crohn's disease with metronidazole. Gastroenterology 1980, 79:357-365.
72. Brandt L.J., Berstein L.H., Boley S.J., et al. Metronidazole therapy for perineal Crohn's disease: a follow-up study. Gastroenterology 1982, 83:383-387.
73. Jakobovits J., Schuster M.M. Metronidazole therapy for Crohn's disease and associated fistulae. Am J Gastroenterol 1984, 79:533-540.
74. Solomon M.J., McLeod R.S., O'Connor B.I., et al. Combination ciprofloxacin and metronidazole in severe perianal Crohn's disease. Can J Gastroenterol 1993, 7:571-573.
75. Thia K.T., Mahadevan U., Feagan B.G., et al. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflammat Bowel Dis 2009, 15:17-24.
76. Pearson D.C., May G.R., Fick G.H., et al. Azathioprine and 6-mercaptopurine in Crohn's disease. A meta-analysis. Ann Intern Med 1995, 123:132-142.
77. Korelitz B.I., Adler D.J., Mendelsohn R.A., et al. Long-term experience with 6-mercaptopurine in the treatment of Crohn's disease. Am J Gastroenterol 1993, 88:1198-1205.
78. Sandborn W.J. A critical review of cyclosporine therapy in inflammatory bowel disease. Inflamm Bowel Dis 1995, 1:48-63.
79. Sandborn W.J., Present D.H., Isaacs K.L., et al. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology 2003, 125:380-388.
80. Sandborn W.J., Fazio V.W., Feagan B.G., et al. AGA technical review on perianal Crohn's disease. Gastroenterology 2003, 125:1508-1530.
81. Present D.H., Rutgeerts P., Targan S., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999, 340:1398-1405.
82. Colombel J.F., Schwartz D.A., Sandborn W.J., et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut 2009, 58:940-948.
83. Sands B.E., Anderson F.H., Bernstein C.N., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004, 350:876-885.
84. Gaertner W.B., Decanini A., Mellgren A., et al. Does infliximab infusion impact results of operative treatment for Crohn's perianal fistulas?. Dis Colon Rectum 2007, 50:1754-1760.
85. Hyder S.A., Travis S.P., Jewell D.P., et al. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment. Dis Colon Rectum 2006, 49:1837-1841.
86. Topstad D.R., Panaccione R., Heine J.A., et al. Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulising anorectal Crohn's disease. A single center experience. Dis Colon Rectum 2003, 46:577-583.
87. van der Hagen S.J., Baeten C.G., Soeters P.B., et al. Anti-TNF-alpha (infliximab) used as induction treatment in case of active proctitis in a multistep strategy followed by definitive surgery of complex anal fistulas in Crohn's disease: a preliminary report. Dis Colon Rectum 2005, 48:758-767.
88. Rutgeerts P., Vermeire S., Van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology 2009, 136:1182-1197.
89. Faubion W.A., Loftus E.V., Harmsen W.S., et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001, 121:255-260.
90. Timmer A., McDonald J.W., Macdonald J.K. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2007, 1:CD000478.
91. Ardizzone S., Maconi G., Russo A., et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006, 55:47-53.
92. Gisbert J.P., Linares P.M., McNicholl A.G., et al. Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther 2009, 30:126-137.
93. Lawson M.M., Thomas A.G., Akobeng A.K. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006, 3:CD005112.
94. Gisbert J.P., González-Lama Y., Maté J. Systematic review: infliximab therapy in ulcerative colitis. Aliment Pharmacol Ther 2007, 25:19-37.
95. Sandborn W.J., Rutgeerts P., Feagan B.G., et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009, 137:1250-1260.
96. Lichtenstein G.R., Diamond R.H., Wagner C.L., et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther 2009, 30:210-226.
97. Ferrante M., Vermeire S., Fidder H., et al. Long-term outcome after infliximab for refractory ulcerative colitis. J Crohn's Colitis 2008, 2:219-225.
98. Toruner M., Loftus E.V., Harmsen W.S., et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008, 134:929-936.
99. Oussalah A., Laclotte C., Chevaux J.B., et al. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. Aliment Pharmacol Ther 2008, 28:966-972.
100. Afif W., Leighton J.A., Hanauer S.B., et al. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis 2009, 15:1302-1307.
101. Reinisch W., Sandborn W.J., Hommes D.W., et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis. J Crohn's Colitis 2010, 4:S5.
102. Truelove S.C., Jewell D.P. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1974, 1:1067-1070.
103. Travis S.P. Review article: the management of mild to severe acute ulcerative colitis. Aliment Pharmacol Ther 2004, 20:88-92.
104. Lichtiger S., Present D.H., Kornbluth A., et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994, 330:1841-1851.
105. Carbonnel F., Boruchowicz A., Duclos B., et al. Intravenous cyclosporine in attacks of ulcerative colitis: short-term and long-term responses. Dig Dis Sci 1996, 41:2471-2476.
106. Arts J., D'Haens G., Zeegers M., et al. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis 2004, 10:73-78.
107. Sands B.E., Tremaine W.J., Sandborn W.J., et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001, 7:83-88.
108. Chey W.Y. Infliximab for patients with refractory ulcerative colitis. Inflamm Bowel Dis 2001, 7:S30-S33.
109. Kaser A., Mairinger T., Vogel W., et al. Infliximab in severe steroid refractory ulcerative colitis: a pilot study. Wien KlinWochenschr 2001, 113:930-933.
110. Kohn A., Prantera C., Pera A., et al. Anti-tumour necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis: result of an open study on 13 patients. Dig Liver Dis 2002, 34:626-630.
111. Actis G.C., Bruno M., Pinna-Pintor M., et al. Infliximab for treatment of steroid-refractory ulcerative colitis. Dig Liver Dis 2002, 34:631-634.
112. Gornet J.M., Couve S., Hassani Z., et al. Infliximab for refractory ulcerative colitis or indeterminate colitis: an open label multicentre study. Aliment Pharmacol Ther 2003, 18:175-181.
113. Daperno M., Sostegni R., Scaglione N., et al. Outcome of a conservative approach in severe ulcerative colitis. Dig Liver Dis 2004, 36:21-28.
114. Jakobovits S.L., Jewel D.P., Travis S.P. Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006. Aliment Pharmacol Ther 2007, 25:1055-1060.
115. Lees C.W., Heys D., Ho G.T., et al. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment Pharmacol Ther 2007, 26:411-419.
116. Bressler B., Law J.K., Al Nahdi Sheraisher N., et al. The use of infliximab for treatment of hospitalized patients with acute severe ulcerative colitis. Can J Gastroenterol 2008, 22:937-940.
117. Jarnerot G., Hertervig E., Friis-Liby I., et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005, 128:1805-1811.
118. Lindgren S.C., Flood L.M., Kilander A.F., et al. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 1998, 10:831-835.
119. Ochsenkuhn T., Sackmann M., Goke B. Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study. Eur J Gastroenterol Hepatol 2004, 16:1167-1171.
120. Armuzzi A., De Pascalis B., Lupascu A., et al. Infliximab in the treatment of steroid-dependent ulcerative colitis. Eur Rev Med Pharmacol Sci 2004, 8:231-233.
121. Kohn A., Daperno M., Armuzzi A., et al. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. Aliment Pharmacol Ther 2007, 26:747-756.
122. Barreiro-de Acosta M., Lorenzo A., Dominguez-Muñoz J.E. Adalimumab in ulcerative colitis: two cases of mucosal healing and clinical response at two years. World J Gastroenterol 2009, 15:3814-3816.
123. Peyrin-Biroulet L., Laclotte C., Roblin X., et al. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open label study. World J Gastroenterol 2007, 13:2328-2332.
124. Bongartz T., Sutton A.J., Sweeting M.J., et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. J Am Med Assoc 2006, 295:2275-2285.
125. Caspersen S., Elkjaer M., Riis L., et al. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol 2008, 6:1212-1217.
126. Biancone L., Orlando A., Kohn A., et al. Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Gut 2006, 55:228-233.
127. Biancone L, Petruzziello C, Orlando A, et al. Cancer in Crohn's diseased patients treated with Infliximab: a long-term multicentre matched pair study. Inflamm Bowel Dis. 2010. [Epub ahead of print].
128. Lichtenstein G.R., Feagan B.G., Cohen R.D., et al. Serious infections and mortality in association with therapies for Crohn's Disease: TREAT Registry. Clin Gastroenterol Hepatol 2006, 4:621-630.
129. Biancone L., Calabrese E., Petruzziello C., et al. Treatment with biologic therapies and the risk of cancer in patients with IBD. Nat Clin Pract Gastroenterol Hepatol 2007, 4:78-91.
130. Siegel C.A., Marden S.M., Persing S.M., et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol 2009, 7:874-881.
131. Sandborn W.J., Hanauer S., Loftus E.V., et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's Disease. Am J Gastroenterol 2004, 99:1984-1989.
132. Papadakis K.A., Shaye O.A., Vasiliauskas E.A., et al. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol 2005, 100:75-79.
133. Loftus E.V., Feagan B.G., Colombel J.F., et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's Disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol 2008, 103:3132-3141.
134. Feagan B.G., Panaccione R., Sandborn W.J., et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology 2008, 135:1493-1499.
135. Colombel J.F., Sandborn W.J., Panaccione R., et al. Adalimumab safety in global clinical trials of patients with Crohn's Disease. Inflamm Bowel Dis 2009, 15:1308-1319.
136. Swaminath A., Ullman T., Rosen M., et al. Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naïve patients. Alim Pharmacol Ther 2009, 29:273-278.
137. Cottone M., Kohn A., Daperno M., et al. Anti TNF therapy in elderly people in IBD: a multicentre survey. J Crohn's Colitis 2010, S59:P116.
138. Rahier J.F., Ben-Horin S., Chowers Y., et al. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohn's Colitis 2009, 3:47-91.
139. Orlando A., Colombo E., Kohn A., et al. Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study. Dig Liver Dis 2005, 37:577-583.
140. Ardizzone S., Maconi G., Colombo E., et al. Perianal fistulae following infliximab treatment: clinical and endosonographic outcome. Inflamm Bowel Dis 2004, 10:91-96.
141. Orlando A., Mocciaro F., Civitavecchia G., et al. Minimizing infliximab toxicity in the treatment of inflammatory bowel disease. Dig Liver Dis 2008, 40:S236-S246.
142. De Silva S., Devlin S., Panaccione R. Optimizing the safety of biologic therapy for IBD. Nat Rev Gastroenterol Hepatol 2010, 7:93-101.
143. Keystone E.C. Safety of biologic therapies-an update. J Rheumatol Suppl 2005, 74:8-12.
144. Keane J., Gershon S., Wise R.P., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001, 345:1098-1104.
145. Ellerin T., Rubin R.H., Weinblatt M.E. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum 2003, 48:3013-3022.
146. Rutgeerts P., Van Assche G., Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004, 126:1593-1610.
147. Gomez-Reino J.J., Carmona L., Angel Descalzo M. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007, 57:756-761.
148. Pai M., Zwerling A., Menzies D. Systematic review: T-cell based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008, 149:177-184.
149. Ben-Horin S., Margalit M., Bossuyt P., et al. Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and Clostridium difficile infection. Clin Gastroenterol Hepatol 2009, 7:981-987.
150. Sands B.E., Cuffari C., Katz J., et al. Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis 2004, 10:677-692.
151. Kaur N., Mahl T.C. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci 2007, 52:1481-1484.
152. Harigai M., Koike R., Miyasaka N. Pneumocystis pneumonia associated with infliximab in Japan. N Engl J Med 2007, 357:1874-1876.
153. Rodriguez M., Fishman J.A. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev 2004, 17:770-782.
154. Raimondo G., Pollicino T., Squadrito G. What is the clinical impact of occult hepatitis B virus infection?. Lancet 2005, 365:638-640.
155. Ostuni P., Botsios C., Punzi L., et al. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 2003, 62:686-687.
156. Esteve M., Saro C., Gonzalez-Huix F., et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004, 53:1363-1365.
157. Madonia S., Orlando A., Scimeca D., et al. Occult hepatitis B and infliximab-induced HBV reactivation. Inflamm Bowel Dis 2007, 13:508-509.
158. Marzano A., Angelucci P., Andreone P., et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 2007, 39:397-408.
159. Parke F.A., Reveille J.D. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum 2004, 51:800-804.
160. Vauloup C., Krzysiek R., Greangeot-Keros L., et al. Effects of tumor necrosis factor antagonist treatment on hepatitis C-related immunological abnormalities. Eur Cytokine Netw 2006, 17:290-293.
161. Cottone M., Pietrosi G., Martorana G., et al. Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn's colitis. Am J Gastroenterol 2001, 96:773-775.
162. Lavagna A., Bergallo M., Daperno M., et al. Infliximab and the risk of latent viruses reactivation in active Crohn's disease. Inflamm Bowel Dis 2007, 13:896-902.
163. Hambleton S., Gershon A.A. Preventing varicella-zoster disease. Clin Microbiol Rev 2005, 18:70-80.
164. Kinder A., Stephens S., Mortimer N., et al. Severe herpes zoster after infliximab infusion. Postgrad Med J 2004, 80:26.
165. Reijasse D., Le Pendeven C., Cosnes J., et al. Epstein-Barr virus viral load in Crohn's disease: effect of immunosuppressive therapy. Inflamm Bowel Dis 2004, 10:85-90.
166. Garrido Serrano A., Perez Martin F., Guerrero Igea F.J., et al. Fatal infectious mononucleosis during azathioprine treatment in Crohn's disease. Gastroenterol Hepatol 2000, 23:7-8.
167. Fiore A.E., Shay D.K., Haber P., et al. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. MMWR Recomm Rep 2007, 56:1-54.
168. Stephenson I., Clark T.W., Pareek M. Antiviral treatment and prevention of seasonal influenza: a comparative review of recommendations in the European Union. J Clin Virol 2008, 42:244-248.
169. D'Haens G. Risks and benefits of biologic therapy for inflammatory bowel diseases. Gut 2007, 56:725-732.
170. Hanauer S.B., Wagner C.L., Bala M., et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004, 2:542-553.
171. Baert F., Noman M., Vermeire S., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003, 348:601-608.
172. Sandborn W.J., Hanauer S.B. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am J Gastroenterol 2002, 97:2962-2972.
173. U.S. Food and Drug Administration. Center for Drug Evaluation and Research. Questions and answers on Remicade/FDA action. Available at: ; May 19, 2006 [accessed 01.08.06]. http://www.fda.gov/cder/drug/infopage/infliximab/qa.htm.
174. Chung E.S., Packer M., Lo K.H., et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003, 107:3133-3140.
175. Saleem G., Li S.C., MacPherson B.R., et al. Hepatitis with interface inflammation and IgG, IgM, and IgA anti-double-stranded DNA antibodies following infliximab therapy: comment on the article by Charles et al. Arthritis Rheum 2001, 44:1966-1968.
176. Menghini V.V., Arora A.S. Infliximab-associated reversible cholestatic liver disease. Mayo Clin Proc 2001, 76:84-86.
177. Colombel J.F., Loftus E.V., Tremaine W.J., et al. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol 2004, 99:878-883.
178. Marchal L., D'Haens G., Van Assche G., et al. The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study. Aliment Pharmacol Ther 2004, 19:749-754.
179. Appau K.A., Fazio V.W., Shen B., et al. Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients. J Gastrointest Surg 2008, 12:1738-1744.
180. Renna S., Cammà C., Modesto I., et al. Meta-analysis of the placebo rates of clinical relapse and severe endoscopic recurrence in postoperative Crohn's disease. Gastroenterology 2008, 135:1500-1509.
181. Cottone M., Rosselli M., Orlando A., et al. Smoking habits and recurrence in Crohn's disease. Gastroenterology 1994, 106:643-648.
182. Simillis C., Yamamoto T., Reese G.E., et al. A meta-analysis comparing incidence of recurrence and indication for reoperation after surgery for perforating versus nonperforating Crohn's disease. Am J Gastroenterol 2008, 103:196-205.
183. Yamamoto T. Factors affecting recurrence after surgery for Crohn's disease. World J Gastroenterol 2005, 11:3971-3979.
184. Doherty G., Bennett G., Patil S., et al. Intervention for prevention of post-operative recurrence of Crohn's disease. Cochrane Database Syst Rev 2009, 4:CD006873.
185. Sorrentino D., Terrosu G., Avellini C., et al. Infliximab with low-dose methotrexate for prevention of postsurgical recurrence of ileocolonic Crohn disease. Arch Intern Med 2007, 167:1804-1807.
186. Sorrentino D., Paviotti A., Terrosu G., et al. Low-dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn's disease. Clin Gastroenterol Hepatol 2010, 8:591-599.
187. Regueiro M., Schraut W., Baidoo L., et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 2009, 136:441-450.
188. Williams H., Walker D., Orchard T.R. Extraintestinal manifestations of inflammatory bowel disease. Curr Gastroenterol Rep 2008, 10:597-605.
189. Orchard T.R., Wordsworth B.P., Jewell D.P. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 1998, 42:387-391.
190. Braun J., Brandt J., Listing J., et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002, 359:1187-1193.
191. Van Den Bosch F., Kruithof E., Baeten D., et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 2002, 46:755-765.
192. Herfarth H., Obermeier F., Andus T., et al. Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn's disease. Am J Gastroenterol 2002, 97:2688-2690.
193. Braun J., Deodhar A., Dijkmans B., et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. Arthritis Rheum 2008, 59:1270-1278.
194. Breban M., Ravaud P., Claudepierre P., et al. Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. Arthritis Rheum 2008, 58:88-97.
195. van der Heijde D., Schiff M.H., Sieper J., et al. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis 2009, 68:922-929.
196. Rispo A., Scarpa R., Di Girolamo E., et al. Infliximab in the treatment of extra-intestinal manifestations of Crohn's disease. Scand J Rheumatol 2005, 34:387-391.
197. Generini S., Giacomelli R., Fedi R., et al. Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis 2004, 63:1664-1669.
198. Su C.G., Judge T.A., Lichtenstein G.R. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Clin North Am 2002, 31:307-327.
199. Reichrath J., Bens G., Bonowitz A., et al. Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol 2005, 53:273-283.
200. Brooklyn T.N., Dunnill M.G., Shetty A., et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 2006, 55:505-509.
201. Barrie A., Regueiro M. Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2007, 13:1424-1429.
202. Cobo-Ibáñez T., del Carmen Ordóñez M., Muñoz-Fernández S., et al. Do TNF-blockers reduce or induce uveitis?. Rheumatology 2008, 47:731-732.
203. Tekkis P.P., Nicholls R.J. Ileal pouch dysfunction: diagnosis and management. Gastroenterol Clin North Am 2008, 37:669-683.
204. Shen B., Fazio V.W., Remzi F.H., et al. Risk factors for diseases of ileal pouch-anal anastomosis after restorative proctocolectomy for ulcerative colitis. Clin Gastroenterol Hepatol 2006, 4:81-89.
205. Viscido A., Habib F.I., Kohn A., et al. Infliximab in refractory pouchitis complicated by fistulae following ileo-anal pouch for ulcerative colitis. Aliment Pharmacol Ther 2003, 17:1263-1271.
206. Calabrese C., Gionchetti P., Rizzello F., et al. Short-term treatment with infliximab in chronic refractory pouchitis and ileitis. Aliment Pharmacol Ther 2008, 27:759-764.
207. Ferrante M., D'Haens G., Dewit O., et al. Efficacy of infliximab in refractory pouchitis and Crohn's disease related complications of the pouch: a Belgian case series. Inflamm Bowel Dis 2010, 16:243-249.
208. Shen B., Remzi F.H., Lavery I.C., et al. Administration of adalimumab in the treatment of Crohn's disease of the ileal pouch. Aliment Pharmacol Ther 2009, 29:519-526.
209. FDA. Regulations. 1980; 44:37434-67.
210. Simister N.E. Placental transport of immunoglobulin G. Vaccine 2003, 21:3365-3369.
211. Treacy G. Using an analogous monoclonal antibody to evaluate the reproductive and chronic toxicity potential for a humanized anti-TNFalpha monoclonal antibody. Hum Exp Toxicol 2000, 19:226-228.
212. Lichtenstein G.R., Cohen R.D., Feagan B.G., et al. Safety of infliximab in Crohn's disease: data from the 5000-patient TREAT registry. Gastroenterology 2004, 126:A54.
213. Katz J.A., Antoni C., Keenan G.F., et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 2004, 99:2385-2392.
214. Mahadevan U., Kane S., Sandborn W.J., et al. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther 2005, 21:733-738.
215. Johnson D.L., Jones K.L., Chambers C.D., et al. Pregnancy outcomes in women exposed to adalimumab: the OTIS autoimmune diseases in pregnancy project. Gastroenterology 2009, 138(Suppl. 1):A127.